At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 86 enrolled
Drug / intervention
Zactima (vandetanib) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Double-blind, Placebo-controlled, Randomised Study to Assess the Efficacy and Safety of Docetaxel (Taxotere)/Prednisolone/ZD6474 vs Docetaxel/Prednisolone/Placebo in Patients With Hormone Refractory Prostrate Cancer (HRPC)
In Brief
A Phase 2 clinical trial evaluating Zactima (vandetanib), Docetaxel, and 1 other intervention for Prostate Cancer and 2 related conditions. Completed, enrolled 86 participants across 11 sites in 5 countries.
Detailed Summary
The purpose of this study is to determine whether treatment with Zactima (vandetanib) in combination with Docetaxel and Prednisolone is more effective than the standard Docetaxel and Prednisolone alone for prostate cancer, in patients with Hormone refractory prostate cancer who have not previously received chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer, Metastatic, Hormone Refractory
CountriesBrazil, Germany, Hungary, South Africa, Sweden
CollaboratorsGenzyme, a Sanofi Company
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2005
Primary CompletionJul 2007
First PostedJul 2007
Study CompletionSep 2008
TodayJul 2026
First PostedJul 10, 2007
Enrollment StartDec 1, 2005
Primary CompletionJul 1, 2007
Study CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 19.0 years ago
Interventions
Zactima (vandetanib)drug
Docetaxeldrug
Prednisolonedrug